Command Palette

Search for a command to run...

Clinical Trials · NCT02109315

Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.

WithdrawnPhase 1Liraglutide (Prohibited)
Phase
Phase 1
Recruitment status
Withdrawn
Sponsor
Anna Cruceta
Enrollment
0
Start date
May 2014
Locations
1 site, Spain
Primary endpoint
Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.
View Liraglutide compound reference